19th International Congress Blue Ribbon Highlights Session - Final Selections

Media Contact:

Elizabeth Clausen, +1 414-276-2145, eclausen@movementdisorders.org

Blue Ribbon Highlights Session Recognizes Best Poster Presentations from 19th International Congress of Parkinson’s Disease and Movement Disorders

SAN DIEGO – The annual Blue Ribbon Highlights Session took place on Thursday, June 18th, during the 19th International Congress of Parkinson’s Disease and Movement Disorders. This special session provides a critical review of the best poster presentations by a panel of experts, highlighting the relevance, nov¬elty, and quality of both clinical and basic research presented by delegates.

Of the 1,473 abstracts accepted for presentation at this year’s International Congress, only 19 were given this special recognition. The Blue Ribbon Highlights Session was chaired by Charles Adler, Scottsdale, AZ, USA and Marcelo Merello, Buenos Aires, Argentina, and the panel was led by Christine Klein, Lübeck, Germany, and David Standaert, Birmingham, AL, USA.

The poster categories selected include physiology, genetics, disease mechanisms, biomarkers, and new therapies. The poster numbers chosen for the 2015 Blue Ribbon Highlights include:


  • 573: Optical neuromodulation of nigrostriatal pathway
  • 1268: Optogenetic modulation of striatal dopaminergic cell translplants in Parkinsonian rats
  • 1325: Sun exposure is an environmental factor for the development of blepharospasm


  • 1177: The Contursi family 20 years later: intrafamilial variability in a kindred with A53T mutation of SCNA gene
  • 1046: A missense mutation in RAB39B causes X-linked dominant Parkinson's disease
  • 1154: Glucocerebrosidase activity in Parkinson’s disease with and without GBA mutations
  • 1167: The impact of rare variants in FUS and HTRA2 on essential tremor

Disease Mechanisms:

  • 1036: CSF derived exosomal microRNA profile in patients with Parkinson’s disease
  • 1266: Enhancement of Lysosomal Biogenesis reverse A53T á-synuclein induced toxicity
  • 909: Detection of alpha-synuclein seeding activity using a novel assay
  • 1385: Microglial dysfunction plays a critical role in Huntington’s disease pathogenesis
  • 1014: Altered response to reward in non-manifesting carriers of the G2019S LRRK2 mutation


  • LBA 14: PREDICT-PD: Identifying risk of Parkinson’s disease in the community
  • 1191: A Simple Approach to Monitoring of Parkinson’s Disease State Using a Smart Phone Platform
  • 33: Gender difference in depletion of presynaptic nigrostriatal dopamine in de novo Parkinson’s disease
  • LBA 20: Tau-PET Imaging in Progressive Supranuclear Palsy Using [18F] AV-1451
  • 95: Metabolomic biospecimen analysis for measuring Parkinson’s disease progression

New Therapies:

  • LBA 8: Stable levodopa plasma levels with ND0612 (levodopa/carbidopa for subcutaneous infusion) in Parkinson’s disease (PD) patients with motor fluctuations
  • 260: Inhaled levodopa (CVT-301) provides rapid improvement of OFF states in Parkinson’s disease

For complete abstracts, Late Breaking Abstracts and author information, visit: http://www.mdscongress2015.org/Congress-2015/Abstracts/Publication.htm

About the 19th International Congress of Parkinson's Disease and Movement Disorders:
Meeting attendees are gathered to learn the latest research findings and state-of-the-art treatment options in Movement Disorders, including Parkinson's disease. Over 3,500 physicians and medical professionals from more than 80 countries are able to view over 1,500 scientific abstracts submitted by clinicians from around the world.

About the International Parkinson and Movement Disorder Society:
The International Parkinson and Movement Disorder Society (MDS), an international society of over 5,000 clinicians, scientists, and other healthcare professionals, is dedicated to improving patient care through education and research. For more information about MDS, visit www.movementdisorders.org.